Trial · NCT06060457
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | Fluzone HD + mRNA-1345 Followed by Placebo | 689 | Participants | ||
| Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | Fluzone HD + Placebo Followed by mRNA-1345 | 547 | Participants | ||
| Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection | Fluzone HD + mRNA-1345 Followed by Placebo | 251 | Participants | ||
| Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection | Fluzone HD + Placebo Followed by mRNA-1345 | 557 | Participants | ||
| Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection | Fluzone HD + mRNA-1345 Followed by Placebo | 72 | Participants | ||
| Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection | Fluzone HD + Placebo Followed by mRNA-1345 | 72 | Participants | ||
| Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection | Fluzone HD + mRNA-1345 Followed by Placebo | 60 | Participants | ||
| Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection | Fluzone HD + Placebo Followed by mRNA-1345 | 71 | Participants | ||
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + mRNA-1345 Followed by Placebo | MAAEs | 194 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + Placebo Followed by mRNA-1345 | MAAEs | 191 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + mRNA-1345 Followed by Placebo | AESIs | 0 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + Placebo Followed by mRNA-1345 | AESIs | 1 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + mRNA-1345 Followed by Placebo | SAEs | 23 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + Placebo Followed by mRNA-1345 | SAEs | 33 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + mRNA-1345 Followed by Placebo | AEs Leading to Discontinuation | 3 | Participants | |
| Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation | Fluzone HD + Placebo Followed by mRNA-1345 | AEs Leading to Discontinuation | 3 | Participants | |
| Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs) | Fluzone HD + mRNA-1345 Followed by Placebo | RSV-A | 11800.26 | 95% Confidence Interval 11063.69 to 12585.87 | IU/mL |
| Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs) | Fluzone HD + Placebo Followed by mRNA-1345 | RSV-A | 18874.12 | 95% Confidence Interval 17670.37 to 20159.87 | IU/mL |
| Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs) | Fluzone HD + mRNA-1345 Followed by Placebo | RSV-B | 4197.74 | 95% Confidence Interval 3949.53 to 4461.54 | IU/mL |
| Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs) | Fluzone HD + Placebo Followed by mRNA-1345 | RSV-B | 6579.15 | 95% Confidence Interval 6178.21 to 7006.11 | IU/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06060457/results